Showing results (101-110 of 122) with videos related to
Sort By:
Pageof 13
Advanced Materials (Deerfield Beach, Fla.)|February 27, 2025
17.68% Efficiency Nonhalogenated Solvent-Processed Organic Solar Cell Modules Driven by Seed Crystal StrategyHaotian Hu, Ze Jin, Jinfeng Ge, et al.International Journal of Molecular Sciences|January 8, 2014
Enhanced antitumor effects of adenoviral-mediated siRNA against GRP78 gene on adenosine-induced apoptosis in human hepatoma HepG2 cellsLing-Fei Wu, Yi-Tian Guo, Qing-Hua Zhang, et al.Journal of Clinical Laboratory Analysis|May 23, 2014
Relationship Between Hematocrit Level and Cardiovascular Risk Factors in a Community-Based PopulationYuan-Ze Jin, Dong-Han Zheng, Zhi-Ying Duan, et al.Frontiers in Cardiovascular Medicine|August 5, 2022
Ablation and antiarrhythmic drug effects on PITX2 +/- deficient atrial fibrillation: A computational modeling studyZe Jin, Inseok Hwang, Byounghyun Lim, et al.Frontiers in Physiology|April 4, 2022
Anti-atrial Fibrillation Effects of Pulmonary Vein Isolation With or Without Ablation Gaps: A Computational Modeling StudyZe Jin, Inseok Hwang, Byounghyun Lim, et al.Journal of Clinical Immunology|April 24, 2023
The Clinical Significance and Prognostic Role of Whole-Blood Epstein-Barr Virus DNA in Lymphoma-Associated Hemophagocytic LymphohistiocytosisJing Zhang, Shuchao Qin, Ze Jin, et al.International Journal of Oncology|December 10, 2015
The mechanism of adenosine-mediated activation of lncRNA MEG3 and its antitumor effects in human hepatoma cellsLi-Xuan Liu, Wei Deng, Xiao-Tao Zhou, et al.International Journal of Oncology|June 20, 2025
[Corrigendum] The mechanism of adenosine‑mediated activation of lncRNA MEG3 and its antitumor effects in human hepatoma cellsLi-Xuan Liu, Wei Deng, Xiao-Tao Zhou, et al.Advanced Materials (Deerfield Beach, Fla.)|December 29, 2025
Dimeric Acceptors Featuring an Electron-Rich Fused-Ring Linker Enable High-Efficiency and Stable Organic Solar Cells and ModulesHaotian Hu, Jinfeng Ge, Pengfei Ding, et al.Journal of Clinical Medicine|May 14, 2022
Differences in Optimal Platelet Reactivity after Potent P2Y12 Inhibitor Treatment in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary InterventionKai Song, Xuan Jin, Moo-Hyun Kim, et al.Pageof 13